Skip to main content
Clinical Trials/NCT02745886
NCT02745886UnknownPhase 4

Chronic Metformin Treatment Induces a Dietary Restriction-like State in Overweight Human

Xiang Guang-da1 site in 1 country60 target enrollmentStarted: April 2016Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 4
Sponsor
Enrollment
60
Locations
1
Primary Endpoint
The differences of gene expression profile among 3 groups.

Study Overview

Brief Summary

The fact that metformin treatment has been associated with reduced risk of cancer and cardiovascular disease raises the possibility of a beneficial role of metformin for other age-related diseases. The actions of metformin resemble the effects of calorie restriction (CR) to some extent, and microarray analyses have shown that metformin induces a gene expression profile that aligns with that of CR in animal. The aim of the study is to investigate whether metformin treatment can induce dietary restriction-like state in human.

Sixty overweight subjects will be included in this study, and participants will be divided 3 groups (20 cases in each group)including metformin group (0.85, twice daily), standard diet group, and CR group. All subjects will be treated 6 months. At the end of this study, blood samples and muscle samples will be obtained.

Detailed Description

Blood samples will be obtained from all individuals. blood lipids, inflammation markers, insulin, glucose, leptin,adiponectin, ala aminotransferase, asp aminotransferase, creatine phosphokinase,lactate dehydrogenase, alkaline phosphatase,bilirubin, cyclo-oxygenase, citrate synthase, renal function, leukocyte telomere length ratio, and telomerase activity will be measured before and after the treatments.Also, hyperinsulinemic-euglycemic clamp will be performed before and after the treatments. Muscle samples will be obtained by biopsy for 9 individuals (3 cases from each group) at the end of the study. Microarray analysis will be performed for the gene expression profile from the muscle samples. Other protein expressions such asadenosine monophosphate-activated protein kinase (AMPK), peroxisome proliferator-activated receptor coactivator 1a (PGC-1a) activity,will be checked by Western blot.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 60 Years (Adult)
Sex
Male
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Overweight

Exclusion Criteria

  • Using any other drugs
  • < 18 years old
  • > 60 years old
  • Mental disorders
  • Surgery history for abdomen

Arms & Interventions

CR group

Other

Calorie restriction diet will be given to this group.

Intervention: Calorie restriction (Behavioral)

Metformin group

Experimental

Metformin 0.85 twice daily for 6 months

Intervention: metformin 0.85 twice daily for 6 months (Drug)

Outcomes

Primary Outcomes

The differences of gene expression profile among 3 groups.

Time Frame: 6 months

The gene expression profile will be checked by microarray, and compared the number differences of pathways among 3 groups.

Secondary Outcomes

  • The differences of insulin sensitivity in 3 groups(6 months)

Investigators

Sponsor
Xiang Guang-da
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Xiang Guang-da

Director of Endocrinol Dept.

Wuhan General Hospital of Guangzhou Military Command

Study Sites (1)

Loading locations...

Similar Trials